A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer

We describe a case of lenvatinib (E7080) associated focal segmental glomerulosclerosis (FSGS) encountered during the treatment of metastatic medullary thyroid cancer. Proteinuria is a relatively common side effect of VEGF-targeted treatments and can occasionally result in treatment discontinuation....

Descripción completa

Detalles Bibliográficos
Autores principales: Fleming, Kathryn, McGuinness, James, Kipgen, David, Glen, Hilary, Spiliopoulou, Pavlina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192131/
https://www.ncbi.nlm.nih.gov/pubmed/30402314
http://dx.doi.org/10.1155/2018/6927639
_version_ 1783363847863664640
author Fleming, Kathryn
McGuinness, James
Kipgen, David
Glen, Hilary
Spiliopoulou, Pavlina
author_facet Fleming, Kathryn
McGuinness, James
Kipgen, David
Glen, Hilary
Spiliopoulou, Pavlina
author_sort Fleming, Kathryn
collection PubMed
description We describe a case of lenvatinib (E7080) associated focal segmental glomerulosclerosis (FSGS) encountered during the treatment of metastatic medullary thyroid cancer. Proteinuria is a relatively common side effect of VEGF-targeted treatments and can occasionally result in treatment discontinuation. Here, we describe a patient who developed secondary FSGS necessitating discontinuation of treatment at first but who was subsequently rechallenged with anti-VEGF-targeted treatment without recurrence of proteinuria. Lenvatinib was a novel experimental agent at the time the treatment took place; however, its recent licensing for the treatment of thyroid malignancies in the UK makes reporting of these adverse effects all the more important now.
format Online
Article
Text
id pubmed-6192131
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-61921312018-11-06 A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer Fleming, Kathryn McGuinness, James Kipgen, David Glen, Hilary Spiliopoulou, Pavlina Case Rep Oncol Med Case Report We describe a case of lenvatinib (E7080) associated focal segmental glomerulosclerosis (FSGS) encountered during the treatment of metastatic medullary thyroid cancer. Proteinuria is a relatively common side effect of VEGF-targeted treatments and can occasionally result in treatment discontinuation. Here, we describe a patient who developed secondary FSGS necessitating discontinuation of treatment at first but who was subsequently rechallenged with anti-VEGF-targeted treatment without recurrence of proteinuria. Lenvatinib was a novel experimental agent at the time the treatment took place; however, its recent licensing for the treatment of thyroid malignancies in the UK makes reporting of these adverse effects all the more important now. Hindawi 2018-10-03 /pmc/articles/PMC6192131/ /pubmed/30402314 http://dx.doi.org/10.1155/2018/6927639 Text en Copyright © 2018 Kathryn Fleming et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Fleming, Kathryn
McGuinness, James
Kipgen, David
Glen, Hilary
Spiliopoulou, Pavlina
A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer
title A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer
title_full A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer
title_fullStr A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer
title_full_unstemmed A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer
title_short A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer
title_sort case of lenvatinib-induced focal segmental glomerulosclerosis (fsgs) in metastatic medullary thyroid cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192131/
https://www.ncbi.nlm.nih.gov/pubmed/30402314
http://dx.doi.org/10.1155/2018/6927639
work_keys_str_mv AT flemingkathryn acaseoflenvatinibinducedfocalsegmentalglomerulosclerosisfsgsinmetastaticmedullarythyroidcancer
AT mcguinnessjames acaseoflenvatinibinducedfocalsegmentalglomerulosclerosisfsgsinmetastaticmedullarythyroidcancer
AT kipgendavid acaseoflenvatinibinducedfocalsegmentalglomerulosclerosisfsgsinmetastaticmedullarythyroidcancer
AT glenhilary acaseoflenvatinibinducedfocalsegmentalglomerulosclerosisfsgsinmetastaticmedullarythyroidcancer
AT spiliopouloupavlina acaseoflenvatinibinducedfocalsegmentalglomerulosclerosisfsgsinmetastaticmedullarythyroidcancer
AT flemingkathryn caseoflenvatinibinducedfocalsegmentalglomerulosclerosisfsgsinmetastaticmedullarythyroidcancer
AT mcguinnessjames caseoflenvatinibinducedfocalsegmentalglomerulosclerosisfsgsinmetastaticmedullarythyroidcancer
AT kipgendavid caseoflenvatinibinducedfocalsegmentalglomerulosclerosisfsgsinmetastaticmedullarythyroidcancer
AT glenhilary caseoflenvatinibinducedfocalsegmentalglomerulosclerosisfsgsinmetastaticmedullarythyroidcancer
AT spiliopouloupavlina caseoflenvatinibinducedfocalsegmentalglomerulosclerosisfsgsinmetastaticmedullarythyroidcancer

Ejemplares similares